Skip to Main content Skip to Navigation
Theses

When engineering new recombinant factor IX molecules meets gene therapy : improvement of factor IX plasma level in patients with haemophilia B?

Abstract : Introduction: Haemophilia B (HB) is an inherited bleeding disorder due to coagulation factor IX (FIX) deficiency. Adeno-associated virus (AAV)-based gene therapy for HB has shown promising results but can cause liver toxicity after administration of high dose of AAV vectors.The design of new transgene expressing modified FIX that would allow injecting fewer doses of AAV is a real challenge. Materials & Methods: Therapeutic transgene expressing human FIX with prolonged half-life due to fusion to mature albumin (hFIX-Alb) or expressing FIX with improved specific activity, hFIX-E410H, were designed and injected to murine animal model. A novel recombinant FIX molecule exhibiting enhanced half-life through fusion to the FXIIIB subunit via activated factor X-cleavable linker was design, produced and characterised. Results: The hFIX-Alb transgene did not increase the plasma FIX clotting activity compared to the transgene expressing wild-type hFIX. Experiments were undertaken to understand the mecanisms responsible for lower expression. The hFIX-E410H transgene, which showed improved specific activity in vitro and in vivo in HB mice, allowed injecting a 2.5-fold lower dose of AAV. The hFIX-LXa-FXIIIB molecule was functional, corrected the generation capacity in HB mice, and exhibited a 3.9-fold and 2.2-fold enhanced half-life in mice and in rats, respectively, compared to wild-type FIX. Conclusion: We have developed and characterised new transgenes expressing modified FIX, and a novel FIX molecule with prolonged half-life, which could become interesting perspectives for the treatment of HB
Document type :
Theses
Complete list of metadatas

Cited literature [558 references]  Display  Hide  Download

https://tel.archives-ouvertes.fr/tel-02058792
Contributor : Abes Star :  Contact
Submitted on : Wednesday, March 6, 2019 - 10:46:07 AM
Last modification on : Monday, February 10, 2020 - 4:36:54 PM
Long-term archiving on: : Friday, June 7, 2019 - 7:47:44 PM

File

TH2018LeQuellecSandra.pdf
Version validated by the jury (STAR)

Identifiers

  • HAL Id : tel-02058792, version 1

Collections

Citation

Sandra Le Quellec. When engineering new recombinant factor IX molecules meets gene therapy : improvement of factor IX plasma level in patients with haemophilia B?. Human health and pathology. Université de Lyon, 2018. English. ⟨NNT : 2018LYSE1011⟩. ⟨tel-02058792⟩

Share

Metrics

Record views

184

Files downloads

442